Clinical Trial Update: A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL [Phase 2]

View source ↗

Summary

Phase II trial evaluating mosunetuzumab in combination with tislelizumab for relapsed/refractory follicular lymphoma. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• LUNSUMIO (mosunetuzumab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Relapsed/Refractory Follicular Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING